

USSN 09/884,319
Graham *et al.*

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-16. (presently cancelled)

17. (presently amended) A composition comprising a An antibody which specifically reacts with the an IL-1-R intracellular ligand protein of claim 5 comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7.

18-25. (presently cancelled)

26. (new) The antibody of claim 17, wherein the IL-1-R intracellular ligand protein consists of the amino acid sequence of SEQ ID NO:2.

27. (new) The antibody of claim 17, wherein the IL-1-R intracellular ligand protein consists of the amino acid sequence of SEQ ID NO:4.

28. (new) The antibody of claim 17, wherein the IL-1-R intracellular ligand protein consists of the amino acid sequence of SEQ ID NO:6.

29. (new) The antibody of claim 17, wherein the IL-1-R intracellular ligand protein consists of the amino acid sequence of SEQ ID NO:7.

30. (new) The antibody of claim 17, wherein said antibody is a neutralizing antibody.

USSN 09/884,319
Graham et al.

31. (new) The antibody of claim 17, wherein said antibody blocks binding of IL-1-R to an IL-1-R intracellular ligand protein consisting of the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7.

32. (new) The antibody of claim 17, wherein said antibody is a polyclonal antibody.

33. (new) The antibody of claim 17, wherein said antibody is a monoclonal antibody.

34. (new) The antibody of claim 17, wherein said antibody is obtained using as an immunogen an IL-1-R intracellular ligand protein with a cysteine residue at the carboxyl terminus, wherein said protein consists of the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7.

a2

35. (new) A pharmaceutical composition comprising the antibody of claim 17 and a pharmaceutically acceptable carrier.

36. (new) The antibody of claim 17, wherein said antibody is an isolated antibody.

37. (new) A neutralizing antibody that binds specifically to an IL-1-R intracellular ligand protein consisting of the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or

USSN 09/884,319
Graham et al.

SEQ ID NO:7 wherein said neutralizing antibody blocks binding of IL-1-R to said IL-1-R
intracellular ligand protein.

a2

38. (new) A pharmaceutical composition comprising the antibody of claim 37 and a
pharmaceutically acceptable carrier.